Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next
generation of cancer immunotherapies, announced the launch of a suite of
online digital corporate communication channels to maintain on-going
direct communication with shareholders. The Company has launched
official portals on various social media channels including Facebook,
Twitter, LinkedIn, and Google+.
The Company has also launched a CEO Blog that will regularly update the
investment community on important topics from the perspective of Daniel
J. O’Connor, Chief Executive Officer of Advaxis. The blog can be found
at http://www.thechairmansblog.com/advaxis/blogs/.
“We are pleased to announce the launch of our new online communication
channels,” commented Daniel J. O’Connor, Chief Executive Officer of
Advaxis. “By utilizing social media channels, we are able to communicate
more effectively and transparently with our shareholders and the public
while maintaining compliance with all securities laws.”
Links to new communications tools can be found here:
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next
generation of cancer immunotherapies. Advaxis’ immunotherapies are based
on a novel platform technology using live, attenuated bacteria to
stimulate the immune system to selectively target cancer cells while
reducing tumor defenses.
ADXS-HPV, Advaxis’ lead immunotherapy for the treatment of
HPV-associated cancers, has improved survival and objective tumor
responses in a Phase 2 trial in 110 patients with recurrent cervical
cancer. Advaxis is now planning the registrational program for ADXS-HPV.
ADXS-HPV is also being evaluated in other HPV-associated cancers
including a Phase 2 in advanced cervical cancer, a Phase 1/2 in head &
neck cancer, and a Phase 1/2 in anal cancer. ADXS-HPV has orphan
drug status for both anal and head and neck cancer. As part of its
global commercialization strategy to enter into regional licensing deals
with other market dominant biopharmaceutical companies in territories
where there is a high prevalence of HPV-associated cancers, Advaxis has
granted an exclusive license for the development and commercialization
of ADXS-HPV in Asia.
ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing
cancers (such as breast, gastric, and other cancers in humans and for
osteosarcoma in canines). Advaxis’ lead animal-health immunotherapy,
ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1
trial in canine osteosarcoma. These data provide the rational to advance
this same immunotherapy into a Phase 1 clinical trial in women with
HER2-positive breast cancer. The Company is preparing to submit an IND
for ADXS-cHER2 in breast cancer in 2014.
Advaxis has created over 15 distinct immunotherapies based on its
platform either directly or through strategic collaborations with
recognized centers of excellence such as: the University
of Pennsylvania, the Georgia
Regents University Cancer Center, the
Icahn School of Medicine at Mount Sinai, and others.
For more information please visit www.advaxis.com
or connect with us on Facebook,
Twitter,
Google+
and LinkedIn.
Copyright Business Wire 2014